American Heart News - Heart News
FEBRUARY 22, 2025
DALLAS, Feb. 22, 2025 More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. Additionally, data from the Statistical Update shows.
The American Journal of Cardiology
FEBRUARY 22, 2025
Publication date: Available online 21 February 2025 Source: The American Journal of Cardiology Author(s): Sandeep Jha, Aaron Shekka Espinosa, Linnea Molander, Angela Poller, Valentyna Sevastianova, Koen Simons, Julia Baranowska, Thorsteinn Gudmundsson, Emanuele Bobbio, Rickard Zeijlon, Carlo Pirazzi, Andreas Martinsson, Tomas Mellberg, Petronella Torild, Joakim Sundstrom, Erik Axel Andersson, Sigurdur Thorleifsson, Sabin Salahuddin, Ahmed Elmahdy, Tetiana Pylova
HCPLive
FEBRUARY 22, 2025
Our top 5 headlines included a new approval for atopic dermatitis, expert consensus on anaphylaxis care, and the end of the semaglutide shortage.
Med Page Today
FEBRUARY 22, 2025
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
HCPLive
FEBRUARY 22, 2025
These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.
NEJM Journal Watch - Cardiology
FEBRUARY 22, 2025
Without guidance, patients often deviate from guidelines and do not perform high-quality measurements.
Dr. S. Venkatesan MD
FEBRUARY 22, 2025
Yes, definitely it is. The risk is very high in patients with DCM and other structural heart diseases. (Typically bundle branch reentry-BBR Ref: Mazur A, Kusniec Indian Pacing Electrophysiol J. 2005 ) What about in normal hearts? However, In normal hearts without LV dysfunction the risk is dramatically lower, but still not totally risk free. (The term normality can be undermined now , because, in true sense , an echocardiogram is not sufffice to rule out a structural myocardial disease.
Expert insights. Personalized for you.
113 
Let's personalize your content